AJOG: In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring
ABSTRACT Background 17α-hydroxyprogesterone caproate is a synthetic progestogen initially approved in the 1950s to treat gynecologic and obstetrical conditions. Despite continued concerns about safety and short-term efficacy regarding the use…